It has been previously reported, that empagliflozin reduced renal inflammation and oxidative stress in spontaneously hypertensive rats [47] In the EMPA-CARD trial patients with type2 diabetes and coronary artery disease treated with empagliflozin had lower levels of interleukin 6, interleukin 1β and CRP levels compared to a placebo. The gene discussed is CRP; the disease is inflammation.